We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

TSTL Tristel Plc

20.00 (4.65%)
30 Nov 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Tristel Plc LSE:TSTL London Ordinary Share GB00B07RVT99 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  20.00 4.65% 450.00 162,022 14:40:42
Bid Price Offer Price High Price Low Price Open Price
445.00 455.00 450.00 430.00 430.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Med, Dental, Hosp Eq-whsl 36.01M 4.46M 0.0941 47.82 213.26M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:34:42 O 33,210 430.00 GBX

Tristel (TSTL) Latest News

Tristel (TSTL) Discussions and Chat

Tristel Forums and Chat

Date Time Title Posts
30/11/202317:05The TRISTEL story3,307
14/9/201813:56MRSA cleaner249
15/7/201512:01Tristel PLC: Cleaning up the sector340
03/1/201004:54tristel with charts-
13/2/200607:10TSTL with Charts & News3

Add a New Thread

Tristel (TSTL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2023-11-30 17:15:00430.0033,210142,803.00O
2023-11-30 17:15:00430.0025,000107,500.00O
2023-11-30 17:15:00430.0047,618204,757.40O
2023-11-30 16:43:45450.0015,00067,500.00O
2023-11-30 16:34:44446.2525,000111,562.50O

Tristel (TSTL) Top Chat Posts

Top Posts
Posted at 30/11/2023 08:20 by Tristel Daily Update
Tristel Plc is listed in the Med, Dental, Hosp Eq-whsl sector of the London Stock Exchange with ticker TSTL. The last closing price for Tristel was 430p.
Tristel currently has 47,390,993 shares in issue. The market capitalisation of Tristel is £213,259,469.
Tristel has a price to earnings ratio (PE ratio) of 47.82.
This morning TSTL shares opened at 430p
Posted at 22/11/2023 19:48 by james188
One other point is that alternative effective solutions to chlorine dioxide tend to have material downsides - e.g. some are corrosive, require material capex investment for machines etc, etc. I hope that TSTL pushes forward hard with its global rollout to materially grow global revenues and prioritises investment over dividend returns. A trade exit is the obvious endgame, but I hope not until the share has rerated - and I know that it is already on a high multiple given existing revenues. I don’t know of many better investment opportunities.
Posted at 22/11/2023 18:46 by apad
I've always been worried about the magic ingredient "it aint what you do .." but it has led to the satisfying of significant regulatory hurdles.
So, even if there is a magic ingredient, first mover advantage means that it's not worth trying to follow.
I also like the systems they have introduced to maintain good practice.
TSTL is my third largest, and a long-term, holding.
Posted at 22/11/2023 10:59 by apad
TSTL have always maintained that their 'secret' formulation makes chlorine work, compared with other products.
Posted at 22/11/2023 08:49 by melton john
Somebody isn't doing their job, I suspect some bean counter has found a cheaper solution. I was very active in TSTL years ago when I wrote this post and earlier.
Posted at 16/10/2023 08:33 by wad collector
Financial Highlights

-- Turnover of GBP36.0m (2022: GBP31.1m), a 16% increase. 22% growth to GBP36.0m from continuing products (2022: GBP29.6m)

-- Overseas sales continue to grow, up 17% to GBP23.5m (2022: GBP20.1m), representing 65% of total sales (2022: 65%)

-- Gross margin increased to 81% (2022: 80%)
-- Adjusted EBITDA* margin of 25% (2022: 24%)
-- Adjusted pre-tax profit* of GBP6.2m (2022: GBP4.5m) slightly above consensus forecasts
-- Reported pre-tax profit of GBP5.1m (2022: GBP1.6m)
-- Adjusted EPS* up 39% to 10.67p (2022: 7.68p). Basic EPS of 9.44p (2022: 2.09p)
-- Dividend per share for the full year up 10% to 10.50p (2022: 9.55p)
-- Cash of GBP9.5m (2022: GBP8.9m), with continued strong operating cashflow of GBP8.4m in the year (2022: GBP5.6m)

* before share-based payments, and impairment of intangibles in FY 2022
Posted at 14/10/2023 13:56 by timbo003
Register for the seminar mentioned in the previous post (which includes a presentation from TSTL) here:
Posted at 14/10/2023 10:41 by sharesoc
ShareSoc is holding its first hybrid event in London on 19th Oct. Hear from Tristel Plc (TSTL) and other healthcare companies like Inspiration Healthcare Group (IHC), Creo Medical Group (CREO), Abingdon Health (ABDX) and GENincode (GENI). 📍🌐 Attend in-person or online. Register: [...]
Posted at 01/9/2023 06:14 by james188
finncap have put out an RNS this morning on the merger with Cenkos. Amongst other things, it states that Geoff Nash has resigned. He has been the key contact for TSTL for many years. I wonder whether TSTL will now change brokers.
Posted at 20/7/2023 13:11 by piedro
A reminder ...

Tristel PLC
12 July 2023

Shareholder Open Day - And Notice of Trading Update
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that it will hold an Open Day for shareholders at the Company's headquarters in Snailwell, Cambridgeshire on Tuesday 25 July 2023 from 11am to 2pm. The Company will also provide an update on trading for the year ended 30 June 2023 on that date.

The day will provide an opportunity for shareholders to meet the Senior Management team, take a tour of the facility and familiarise themselves with the Company's products.

Availability is limited so please contact Walbrook PR via or call 020 7933 8780 to reserve an entry ticket.

For those that are unable to make it in person, a recording of the presentation will be made available on the Company's website, shortly after the event here: Questions can be pre-submitted in advanced of the meeting via and answers, where appropriate, will be addressed in the presentation.
Posted at 23/2/2021 17:25 by james188
There are many possible reasons for the recent TSTL share price activity (including IG recently deciding to withdraw from small cap stocks), but it does not matter much to medium and long term holders.

Over time in recent years, the share price trajectory has been excellent and there is an obvious roll out strategy which is by no means solely reliant on North America. The company has barely got started in South-East Asia, has no presence in South America and is now projecting initial sales in India next month. The fact that the company remains debt free and relatively conservative are significant plusses for me. The end game may well be TSTL being acquired by a much larger fish, but why not enjoy the ride?
Tristel share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |